You are here: Industry Insights > AbbVie

News List

AbbVie Announces Positive Phase 3 Data for Atogepant in Migraine Prevention americanpharmaceuticalreview
August 06, 2020
AbbVie announced that the Phase 3 ADVANCE trial evaluating the investigational medicine atogepant, an orally administered calcitonin gene-related peptide (CGRP) receptor antagonist (gepant) met its primary endpoint of statistically significantly ...
Study Shows RINVOQ, Topical Corticosteroids Improves Atopic Dermatitis Symptoms americanpharmaceuticalreview
August 04, 2020
AbbVie announced upadacitinib (15 mg and 30 mg, once daily) plus topical corticosteroids (TCS) met the co-primary endpoints and all secondary endpoints in AD Up, the third pivotal Phase 3 study of RINVOQ in atopic dermatitis.
AbbVie, Amgen and Takeda jointly study impact of anti-inflammatory drugs in COVID-19 treatment expresspharma
August 04, 2020
I-SPY COVID will evaluate the impact of cenicriviroc, Otezla, and Firazyr on inflammatory response in severely ill, hospitalised COVID-19 patients.
AbbVie's Rinvoq hits targets in atopic dermatitis trial pharmatimes
July 23, 2020
AbbVie's Rinvoq (upadacitinib) monotherapy has hit both primary and secondary targets in the Measure Up 2 trial, the second Phase III study in individuals with moderate to severe atopic dermatitis.
Sosei, AbbVie sign drug discovery deal worth up to $1 billion expresspharma
June 28, 2020
The partnership will initially focus on the discovery of novel small molecules, targeting inflammatory and autoimmune diseases, the companies said in a news release.
AbbVie's Rinvoq shows potential for atopic dermatitis pharmatimes
June 22, 2020
AbbVie has presented new data showing that Rinvoq (upadacitinib) monotherapy induced significant improvements in skin clearance in people with atopic dermatitis.
Alpine Immune and AbbVie sign $865m immunology deal pharmaceutical-technology
June 22, 2020
Clinical-stage immunotherapy firm Alpine Immune Sciences and biopharmaceutical company AbbVie have signed an option and license agreement potentially worth $805m, for ALPN-101 drug.
Novel Antibody Drug Conjugate ABBV-3373 Shows Improvement in Rheumatoid Arthritis americanpharmaceuticalreview
June 19, 2020
AbbVie announced new data from a Phase 2a study of ABBV-3373, an investigational anti-tumor necrosis factor (TNF) Glucocorticoid Receptor Modulator (GRM) steroid antibody drug conjugate (ADC), in adult patients with ...
AbbVie's Venclyxto shows promise as AML treatment pharmatimes
June 17, 2020
AbbVie has presented new data showing the potential of Venclyxto (venetoclax) to reduce the risk of death in previously untreated patients with acute myeloid leukaemia (AML) who were ineligible for intensive chemotherapy.
AbbVie and Genmab link for oncology collaboration pharmatimes
June 16, 2020
AbbVie and Genmab have signed a pact to jointly develop and commercialise three of the latter's early-stage investigational bispecific antibody product candidates ...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 28 29 Next page